作者
Hao Liu, Mark D'Alesio, Samer AlMasri, Abdulrahman Hammad, Annissa Desilva, Steven Lebowitz, Caroline Rieser, Eishan Ashwat, Erica Hampton, Hussein Khachfe, Mckenna Laffey, Aatur Singhi, Nathan Bahary, Kenneth Lee, Amer Zureikat, Alessandro Paniccia
发表日期
2023/5/1
期刊
HPB
卷号
25
期号
5
页码范围
521-532
出版商
Elsevier
简介
Background/purpose
Neoadjuvant chemotherapy (NAC) is gaining popularity over a surgery-first (SF) approach in treating resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC). However, what constitutes effective neoadjuvant chemotherapy is unknown.
Methods
We retrospectively analyzed resectable and borderline resectable PDAC patients who underwent pancreaticoduodenectomy (2010–2019) at a single institution. Optimal CA19-9 response was defined as normalization AND >50% reduction. We utilized Kaplan-Meier and multivariable-adjusted Cox models and competing risk subdistribution methods for statistical analysis.
Results
586 patients were included in this study. The multivariable-adjusted analysis demonstrated OS benefit in the NAC group only when OS was calculated from diagnosis (HR = 0.72, p = 0.02), but not from surgery (HR = 0.81, p = 0.1). However, in 59 patients …
学术搜索中的文章
H Liu, M D'Alesio, S AlMasri, A Hammad, A Desilva… - HPB, 2023